Propiverine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Propiverine
Accession Number
DB12278
Type
Small Molecule
Groups
Investigational
Description

Propiverine has been investigated for the treatment of Overactive Bladder, Urinary Incontinence, Urinary Bladder, Overactive, and Overactive Bladder Syndrome.

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Propiverine HydrochlorideDC4GZD10H3 54556-98-8KFUJMHHNLGCTIJ-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MictorylCapsule, extended release30 mgOralDuchesnay Inc.2017-05-08Not applicableCanada
MictorylCapsule, extended release45 mgOralDuchesnay Inc.2017-05-08Not applicableCanada
Mictoryl PediatricTablet5 mgOralDuchesnay Inc.2017-04-13Not applicableCanada
Categories
UNII
468GE2241L
CAS number
60569-19-9
Weight
Average: 367.4813
Monoisotopic: 367.214743799
Chemical Formula
C23H29NO3
InChI Key
QPCVHQBVMYCJOM-UHFFFAOYSA-N
InChI
InChI=1S/C23H29NO3/c1-3-18-26-23(19-10-6-4-7-11-19,20-12-8-5-9-13-20)22(25)27-21-14-16-24(2)17-15-21/h4-13,21H,3,14-18H2,1-2H3
IUPAC Name
1-methylpiperidin-4-yl 2,2-diphenyl-2-propoxyacetate
SMILES
CCCOC(C(=O)OC1CCN(C)CC1)(C1=CC=CC=C1)C1=CC=CC=C1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe therapeutic efficacy of Propiverine can be decreased when used in combination with 1,10-Phenanthroline.Experimental
AclidiniumAclidinium may increase the anticholinergic activities of Propiverine.Approved
AlcuroniumThe risk or severity of adverse effects can be increased when Propiverine is combined with Alcuronium.Experimental
AlfentanilThe risk or severity of adverse effects can be increased when Propiverine is combined with Alfentanil.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Propiverine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Propiverine is combined with Alphaprodine.Illicit
AmbenoniumThe therapeutic efficacy of Propiverine can be decreased when used in combination with Ambenonium.Approved
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Propiverine.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Propiverine is combined with Atracurium.Experimental
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Propiverine.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Propiverine.Approved, Vet Approved
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Propiverine.Withdrawn
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Propiverine.Approved
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Propiverine.Approved
BezitramideThe risk or severity of adverse effects can be increased when Propiverine is combined with Bezitramide.Experimental, Illicit, Withdrawn
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Propiverine.Approved
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with Propiverine.Experimental
Botulinum Toxin Type APropiverine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BPropiverine may increase the anticholinergic activities of Botulinum Toxin Type B.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Propiverine is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Propiverine is combined with Butorphanol.Approved, Illicit, Vet Approved
CarfentanilThe risk or severity of adverse effects can be increased when Propiverine is combined with Carfentanil.Illicit, Vet Approved
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Propiverine.Approved, Vet Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Propiverine.Withdrawn
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Propiverine.Approved
CimetropiumPropiverine may increase the anticholinergic activities of Cimetropium.Experimental
CodeineThe risk or severity of adverse effects can be increased when Propiverine is combined with Codeine.Approved, Illicit
CoumaphosThe therapeutic efficacy of Propiverine can be decreased when used in combination with Coumaphos.Vet Approved
CyclopenthiazideThe serum concentration of Cyclopenthiazide can be increased when it is combined with Propiverine.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Propiverine.Approved
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Propiverine.Approved, Investigational
DecamethoniumThe therapeutic efficacy of Propiverine can be decreased when used in combination with Decamethonium.Approved
DemecariumThe therapeutic efficacy of Propiverine can be decreased when used in combination with Demecarium.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Propiverine.Approved, Investigational
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Propiverine.Withdrawn
DextromoramideThe risk or severity of adverse effects can be increased when Propiverine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Propiverine is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Propiverine is combined with Dezocine.Approved
DichlorvosThe therapeutic efficacy of Propiverine can be decreased when used in combination with Dichlorvos.Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Propiverine.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Propiverine is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Propiverine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Propiverine is combined with Dihydromorphine.Experimental, Illicit
DiphenoxylateThe risk or severity of adverse effects can be increased when Propiverine is combined with Diphenoxylate.Approved, Illicit
DistigmineThe therapeutic efficacy of Propiverine can be decreased when used in combination with Distigmine.Experimental
DonepezilThe therapeutic efficacy of Propiverine can be decreased when used in combination with Donepezil.Approved
DPDPEThe risk or severity of adverse effects can be increased when Propiverine is combined with DPDPE.Investigational
DronabinolPropiverine may increase the tachycardic activities of Dronabinol.Approved, Illicit
EchothiophateThe therapeutic efficacy of Propiverine can be decreased when used in combination with Echothiophate.Approved
EdrophoniumThe therapeutic efficacy of Propiverine can be decreased when used in combination with Edrophonium.Approved
EluxadolinePropiverine may increase the constipating activities of Eluxadoline.Approved
EmeproniumThe risk or severity of adverse effects can be increased when Propiverine is combined with Emepronium.Experimental
EtanautineThe risk or severity of adverse effects can be increased when Propiverine is combined with Etanautine.Experimental
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Propiverine.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Propiverine is combined with Ethylmorphine.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Propiverine is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Propiverine is combined with Etybenzatropine.Experimental
FentanylThe risk or severity of adverse effects can be increased when Propiverine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Propiverine can be decreased when used in combination with Fenthion.Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Propiverine.Approved
GalantamineThe therapeutic efficacy of Propiverine can be decreased when used in combination with Galantamine.Approved
GallamineThe risk or severity of adverse effects can be increased when Propiverine is combined with Gallamine.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Propiverine.Approved
Ginkgo bilobaThe therapeutic efficacy of Propiverine can be decreased when used in combination with Ginkgo biloba.Approved, Nutraceutical
Glucagon recombinantThe risk or severity of adverse effects can be increased when Propiverine is combined with Glucagon recombinant.Approved
GlycopyrroniumPropiverine may increase the anticholinergic activities of Glycopyrronium.Approved, Investigational, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Propiverine is combined with Heroin.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Propiverine.Experimental
HomatropineThe risk or severity of adverse effects can be increased when Propiverine is combined with Homatropine.Approved
Huperzine AThe therapeutic efficacy of Propiverine can be decreased when used in combination with Huperzine A.Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Propiverine.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Propiverine is combined with Hydrocodone.Approved, Illicit
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Propiverine.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Propiverine is combined with Hydromorphone.Approved, Illicit
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Propiverine.Approved
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Propiverine.Approved
IpidacrineThe therapeutic efficacy of Propiverine can be decreased when used in combination with Ipidacrine.Experimental
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Propiverine.Approved
IsoflurophateThe therapeutic efficacy of Propiverine can be decreased when used in combination with Isoflurophate.Approved, Withdrawn
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Propiverine.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Propiverine is combined with Ketobemidone.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Propiverine is combined with Levomethadyl Acetate.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Propiverine is combined with Levorphanol.Approved
LofentanilThe risk or severity of adverse effects can be increased when Propiverine is combined with Lofentanil.Illicit
MalathionThe therapeutic efficacy of Propiverine can be decreased when used in combination with Malathion.Approved, Investigational
MazaticolThe risk or severity of adverse effects can be increased when Propiverine is combined with Mazaticol.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Propiverine.Approved
MefloquineThe therapeutic efficacy of Propiverine can be decreased when used in combination with Mefloquine.Approved
MemantineThe therapeutic efficacy of Propiverine can be decreased when used in combination with Memantine.Approved, Investigational
MeptazinolThe risk or severity of adverse effects can be increased when Propiverine is combined with Meptazinol.Experimental
MethadoneThe risk or severity of adverse effects can be increased when Propiverine is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Propiverine is combined with Methadyl Acetate.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Propiverine can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Propiverine.Approved
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Propiverine.Approved
Methyl salicylateThe therapeutic efficacy of Propiverine can be decreased when used in combination with Methyl salicylate.Approved, Vet Approved
MetixeneThe risk or severity of adverse effects can be increased when Propiverine is combined with Metixene.Approved
MetoclopramideThe therapeutic efficacy of Propiverine can be decreased when used in combination with Metoclopramide.Approved, Investigational
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Propiverine.Approved
MianserinMianserin may increase the anticholinergic activities of Propiverine.Approved
MinaprineThe therapeutic efficacy of Propiverine can be decreased when used in combination with Minaprine.Approved
MirabegronThe risk or severity of adverse effects can be increased when Propiverine is combined with Mirabegron.Approved
MorphineThe risk or severity of adverse effects can be increased when Propiverine is combined with Morphine.Approved, Investigational
NabilonePropiverine may increase the tachycardic activities of Nabilone.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Propiverine is combined with Nalbuphine.Approved
NeostigmineThe therapeutic efficacy of Propiverine can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NicomorphineThe risk or severity of adverse effects can be increased when Propiverine is combined with Nicomorphine.Experimental
NormethadoneThe risk or severity of adverse effects can be increased when Propiverine is combined with Normethadone.Approved, Illicit
OpiumThe risk or severity of adverse effects can be increased when Propiverine is combined with Opium.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Propiverine.Approved
OtiloniumThe risk or severity of adverse effects can be increased when Propiverine is combined with Otilonium.Experimental
OxitropiumThe risk or severity of adverse effects can be increased when Propiverine is combined with Oxitropium.Investigational
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Propiverine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Propiverine is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Propiverine is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Propiverine.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Propiverine.Approved
ParaoxonThe therapeutic efficacy of Propiverine can be decreased when used in combination with Paraoxon.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Propiverine is combined with Pentazocine.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Propiverine.Approved
PethidineThe risk or severity of adverse effects can be increased when Propiverine is combined with Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Propiverine is combined with Phenazocine.Experimental
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with Propiverine.Experimental
PhenoperidineThe risk or severity of adverse effects can be increased when Propiverine is combined with Phenoperidine.Experimental
PhysostigmineThe therapeutic efficacy of Propiverine can be decreased when used in combination with Physostigmine.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Propiverine.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Propiverine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Propiverine is combined with Piritramide.Investigational
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Propiverine.Approved
Potassium ChloridePropiverine may increase the ulcerogenic activities of Potassium Chloride.Approved, Withdrawn
PramlintidePramlintide may increase the anticholinergic activities of Propiverine.Approved, Investigational
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Propiverine.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Propiverine.Approved
PyridostigmineThe therapeutic efficacy of Propiverine can be decreased when used in combination with Pyridostigmine.Approved
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Propiverine.Approved
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Propiverine.Approved
RamosetronPropiverine may increase the constipating activities of Ramosetron.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Propiverine is combined with Remifentanil.Approved
RivastigmineThe therapeutic efficacy of Propiverine can be decreased when used in combination with Rivastigmine.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Propiverine.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Propiverine.Approved, Vet Approved
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Propiverine.Approved, Investigational
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Propiverine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Propiverine is combined with Sufentanil.Approved, Investigational
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Propiverine.Approved
TacrineThe therapeutic efficacy of Propiverine can be decreased when used in combination with Tacrine.Withdrawn
TapentadolThe risk or severity of adverse effects can be increased when Propiverine is combined with Tapentadol.Approved
TilidineThe risk or severity of adverse effects can be increased when Propiverine is combined with Tilidine.Experimental
TiotropiumPropiverine may increase the anticholinergic activities of Tiotropium.Approved
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Propiverine.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Propiverine is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Propiverine is combined with Tramadol.Approved, Investigational
TrichlorfonThe therapeutic efficacy of Propiverine can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Propiverine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Propiverine.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Propiverine.Approved
TropatepineThe risk or severity of adverse effects can be increased when Propiverine is combined with Tropatepine.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Propiverine.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Propiverine.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Propiverine.Approved
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Propiverine.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Propiverine.Approved
Food Interactions
Not Available

References

Synthesis Reference
Not Available
General References
Not Available
External Links
Human Metabolome Database
HMDB41999
KEGG Compound
C07852
ChemSpider
4773
ChEBI
8493
ChEMBL
CHEMBL1078261
ATC Codes
G04BD06 — Propiverine
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Not Available
MSDS
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedNot AvailableOveractive Bladder1
3CompletedTreatmentBladder Disorder, Neurogenic / Neurogenic Bladder Disorder / Neurogenic Urinary Bladder Disorder / Overactive Detrusor Function / Urinary Bladder Disorder, Neurogenic / Urinary Bladder Neurogenic Dysfunction / Urinary Bladder, Neurogenic / Urinary Incontinence (UI) / Urologic Diseases1
3CompletedTreatmentOveractive Bladder1
3CompletedTreatmentUrinary Bladder, Overactive1
4CompletedNot AvailableOveractive Bladder Syndrome1
4CompletedTreatmentOveractive Bladder1
4CompletedTreatmentOveractive Bladder (OAB)1
Not AvailableCompletedTreatmentUrinary Incontinence (UI)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Capsule, extended releaseOral30 mg
Capsule, extended releaseOral45 mg
TabletOral5 mg
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00635 mg/mLALOGPS
logP4.16ALOGPS
logP4.25ChemAxon
logS-4.8ALOGPS
pKa (Strongest Basic)8.72ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area38.77 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity107.73 m3·mol-1ChemAxon
Polarizability41.88 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of chemical entities known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom
Chemical entities
Super Class
Organic compounds
Class
Benzenoids
Sub Class
Benzene and substituted derivatives
Direct Parent
Diphenylmethanes
Alternative Parents
Benzylethers / Piperidines / Trialkylamines / Carboxylic acid esters / Amino acids and derivatives / Monocarboxylic acids and derivatives / Dialkyl ethers / Azacyclic compounds / Organopnictogen compounds / Organic oxides
show 2 more
Substituents
Diphenylmethane / Benzylether / Piperidine / Amino acid or derivatives / Carboxylic acid ester / Tertiary amine / Tertiary aliphatic amine / Carboxylic acid derivative / Dialkyl ether / Ether
show 13 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
diarylmethane (CHEBI:8493 )

Drug created on October 20, 2016 15:48 / Updated on October 02, 2017 06:28